NCT07269366 Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function (STICH 3.0-NL)
| NCT ID | NCT07269366 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Medical Center Groningen |
| Condition | Coronary Artery Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 358 participants |
| Start Date | 2026-05 |
| Primary Completion | 2034-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 358 participants in total. It began in 2026-05 with a primary completion date of 2034-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized multicenter trial compares coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) in 358 patients with ischemic left ventricular dysfunction and multivessel coronary disease. The study evaluates differences in survival, major cardiovascular events, and quality of life over 4 years, and contributes to the international STICH 3.0 collaboration assessing long-term outcomes.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * LVEF≤ 40% * Angina pectoris, CCS≥2 and/or hospitalization for ACS or heart failure within 1 year prior to randomization * Multivessel CAD (2-3 vessel-disease with coronary lesions \>70% and involvement of proximal LAD, and/or LM stenosis of \>50%). Target vessels are determined by the local Heart Time * Clinical and angiographical characteristics suitable for isolated coronary revascularization both by CABG or PCI according to the judgment of the local Heart Team * Written informed consent Exclusion Criteria: * ACS \< 48 hours before randomization * Valvular/structural heart disease requiring intervention * Contra-indications to DAPT * Non-cardiac condition with life expectancy \< 1 year * Previous CABG * Decompensated HF at the time of inclusion
Contact & Investigator
Erik Lipsic, Dr
PRINCIPAL INVESTIGATOR
University Medical Center Groningen
Frequently Asked Questions
Who can join the NCT07269366 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07269366 currently recruiting?
Yes, NCT07269366 is actively recruiting participants. Contact the research team at e.lipsic@umcg.nl for enrollment information.
Where is the NCT07269366 trial being conducted?
This trial is being conducted at Groningen, Netherlands.
Who is sponsoring the NCT07269366 clinical trial?
NCT07269366 is sponsored by University Medical Center Groningen. The principal investigator is Erik Lipsic, Dr at University Medical Center Groningen. The trial plans to enroll 358 participants.